latest update:
[TrialBase DB]

trial summary · NCT07221825

Low-Count Quantitative SPECT for Men Treated With Radium-223

Trial record from the TrialBase DB dataset, status RECRUITING, condition Prostate Cancer, sponsored by Washington University School of Medicine. Facts below are exported values from the current release, not inferred or edited prose.

registry NCT07221825phase —enrollment 38start 2026-11-01

Summary

The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.

Internal radiotherapies (radiolabeled molecules that are systemically administered and localize to sites of disease) provide cancer-ablating doses to diseased cells while sparing adjacent normal tissues. \[223Ra\]RaCl2 (Xofigo) is the first FDA-approved alpha-particle emitting radiopharmaceutical therapy (αRPT), providing a survival benefit for men with bone metastatic castration-resistant prostate cancer. Systemically administered radiotherapies distribute throughout the patient, accumulating to unknown levels at sites of disease and in radiosensitive vital organs. The whole-body distribution means that absorbed doses in the patient extend far beyond a pre-defined treatment field. There is a lack of information about αRPT distribution and localization, and this confounds treatment monitoring, complicates dose and schedule personalization, and impedes drug development. Single-photon emission computed tomography (SPECT) imaging offers a mechanism to quantify uptake; however, αRPT administered activities are significantly lower than those used with diagnostic procedures, which presents a challenge for quantitation with conventional methods. Preliminary research shows that low-count quantitative SPECT (LC-QSPECT) imaging demonstrates reliable quantitation of regional uptake for αRPTs. The purpose of this study is to demonstrate the feasibility, tolerability and performance of LC-QSPECT imaging.

Source record: https://clinicaltrials.gov/study/NCT07221825

Facts

registry idNCT07221825
primary registryclinicaltrials-gov
recruitment statusRECRUITING
phasenot reported
study typeINTERVENTIONAL
lead conditionProstate Cancer
sponsorWashington University School of Medicine
sponsor classOTHER
enrollment38
start date2026-11-01
primary completion2028-04-30
completion2028-07-31
results postednot reported

Conditions

  • Prostate Cancer
  • Cancer of the Prostate

Interventions

  • Low-count quantitative single-photon emission computed tomography imaging

Countries

  • United States

Intervention types: DEVICE

Work with this record